NCM · Financial Statements

Avalo Therapeutics, Inc. (AVTX) Financial Statements

$6.93 NCM: AVTX Market Cap $371.66M

Avalo Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $78.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Avalo Therapeutics, Inc.: Revenue fell from $1.0M in 2016 to $0 in 2025, a change of -100.0% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -1394.6% to -123601.7%, a shift of -122207.1 percentage points; the most recent year shows a net loss of $78.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$1.0M$28.0M$18.0M$7.0M$7.0M$5.0M$18.0M$2.0M$0$0
Operating Expenses$17.0M$14.0M$58.0M$23.0M$7.0M$88.0M$55.0M$29.0M$69.0M$73.0M
Operating Profit$-16.0M$14.0M$-39.0M$-16.0M$0$-82.0M$-37.0M$-27.0M$-69.0M$-73.0M
Operating Margin-1394.6%49.9%-214.5%-239.1%0.0%-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Other Income$0$0$0$0$-67.0M$-2.0M$-4.0M$-4.0M$33.0M$-5.0M
Interest$0$0$0$0$0$2.0M$4.0M$3.0M$0$0
Depreciation$0$0$2.0M$4.0M$2.0M$2.0M$0$0$0$0
Profit Before Tax$-16.0M$14.0M$-40.0M$-16.0M$-67.0M$-85.0M$-42.0M$-32.0M$-35.0M$-78.0M
Tax$-2.2M$14.2M$80,000$-1.8M$4.2M$230,000$-70,000$-40,000$-330,000$-210,000
Net Profit$-16.0M$12.0M$-40.0M$-16.0M$-63.0M$-84.0M$-42.0M$-32.0M$-35.0M$-78.0M
EPS$-21.93$1822.74$-3317.28$-819.74$-2523.77$-2330.66$-1062.65$-113.58$-3.26$-5.84
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$1.0M$0$0$0$0$0$0$0$0$0$0
Operating Expenses$4.0M$4.0M$33.0M$10.0M$13.0M$14.0M$15.0M$19.0M$19.0M$20.0M$21.0M$32.0M
Operating Profit$-4.0M$-4.0M$-33.0M$-10.0M$-13.0M$-13.0M$-15.0M$-19.0M$-19.0M$-20.0M$-21.0M$-32.0M
Operating Margin-1589.0%-656.9%0.0%0.0%-5165.1%-6932.8%0.0%0.0%0.0%-33461.0%0.0%0.0%
Interest$2.0M$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-5.0M$-8.0M$-121.0M$98.0M$23.0M$-35.0M$-13.0M$-21.0M$-31.0M$-14.0M$-20.0M$-36.0M
Tax$-150,000$110,000$-10,000$10,000$-60,000$-320,000$-60,000$-80,000$-40,000$-960,000$-60,000$-50,000
Net Profit$-5.0M$-8.0M$-121.0M$98.0M$23.0M$-35.0M$-13.0M$-21.0M$-31.0M$-14.0M$-20.0M$-36.0M
EPS$-26.83$-10.19$-141.14$12.87$2.14$10.47$-1.25$-1.92$-2.19$-0.74$-0.98$-0.83

Over the 10 years reported for Avalo Therapeutics, Inc., borrowings increased from $2.0M in 2016 to $2.0M in 2025, cash stood at $16.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 8.08 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$6.0M$43.0M$70.0M$36.0M$44.0M$80.0M$33.0M$21.0M$151.0M$116.0M
Current Assets$6.0M$11.0M$22.0M$18.0M$26.0M$62.0M$16.0M$8.0M$139.0M$105.0M
Cash$5.0M$2.0M$11.0M$4.0M$19.0M$55.0M$13.0M$7.0M$135.0M$16.0M
Inventory$0$0$1.0M$0$0$0$0$0$0$0
Receivables$0$3.0M$6.0M$5.0M$4.0M$5.0M$2.0M$0$1.0M$0
Fixed Assets$0$0$1.0M$1.0M$2.0M$3.0M$2.0M$2.0M$1.0M$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$8.0M$0$0$0$0$0$82.0M
Other Assets$0$14.0M$16.0M$14.0M$14.0M$14.0M$14.0M$11.0M$11.0M$11.0M
Total Liabilities$6.0M$15.0M$49.0M$15.0M$19.0M$57.0M$44.0M$14.0M$18.0M$33.0M
Current Liabilities$4.0M$11.0M$26.0M$12.0M$15.0M$20.0M$22.0M$5.0M$7.0M$13.0M
Borrowings$2.0M$0$15.0M$0$0$33.0M$20.0M$1.0M$1.0M$2.0M
Other Liabilities$3.0M$15.0M$34.0M$15.0M$19.0M$24.0M$24.0M$13.0M$17.0M$31.0M
Equity$0$3.0M$0$0$0$0$0$0$0$0
Reserves$0$28.0M$21.0M$21.0M$25.0M$23.0M$-11.0M$7.0M$133.0M$83.0M

For Avalo Therapeutics, Inc., operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was negative at $51.0M; free cash flow was positive in 1 of 10 years; financing activities used $1.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-15.0M$13.0M$-3.0M$-19.0M$-41.0M$-71.0M$-27.0M$-31.0M$-49.0M$-51.0M
Investing Cash Flow$0$-19.0M$0$-1.0M$11.0M$0$0$0$0$-82.0M
Financing Cash Flow$0$0$7.0M$0$0$2.0M$0$0$60.0M$-1.0M
Net Cash Flow$-16.0M$-3.0M$8.0M$-7.0M$15.0M$36.0M$-41.0M$-6.0M$127.0M$-119.0M
Free Cash Flow$-15.0M$12.0M$-4.0M$-19.0M$-41.0M$-71.0M$-27.0M$-31.0M$-49.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-7.03
FCF Yield-8.42%
Quick Ratio19.31
Interest Coverage—
Return 1Y275.92%
Return 3Y-76.88%
Return 5Y-99.78%

Avalo Therapeutics, Inc. (AVTX) financials — frequently asked questions

What is Avalo Therapeutics, Inc.'s annual revenue?

Avalo Therapeutics, Inc. (AVTX) reported annual revenue of $0 in its most recent fiscal year.

What is Avalo Therapeutics, Inc.'s net profit?

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $78.0M in its most recent fiscal year.

What is AVTX EV/EBITDA?

Avalo Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -7.03. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
AVTX Overview AVTX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.